New laboratory research shows that a monoclonal antibody made in the laboratory can completely prevent human mammals from becoming infected with the HIV virus. Scientists hope that the same antibody will help prevent humans from becoming infected in the future.
Results In this study, In the future will lead to a human clinical trial in which the antibody “Loronolimab” is evaluated as a factor in preventing human infection with the HIV virus.
“Jonah Sacha, a professor at Oregon University of Health and Science and a senior researcher, says:”
“The findings of our study suggest that leronolimab antibody could be a new weapon against the HIV epidemic.”
“The researcher and professor of medical immunology at the Will Cornell Graduate School of Medical Sciences in New York,” said Dr. Lishomova Nedlow, “
“The results of this preclinical study targeting the HIV receptor, CCR5, could be a new development because we basically have a tool that can mimic CCR5 genetic mutations, which makes some people immune to infection and, to some extent, leads to infection.” “There are two ways to treat HIV.”
To evaluate the effectiveness of leronolimab antibody as a prophylactic drug, the research team formed three groups of six rhesus monkeys, two of which received different doses of leronolimab and the third group did not receive any medication.
Monkeys receiving weekly doses above 50 mg (per kg of animal weight) were completely protected against the HIV virus (monkey species). In contrast, two monkeys receiving a lower dose (10 mg) weekly were infected with all members of the third group. The researchers concluded that the partial protection of the lower-dose group was probably due to their immune system responses to human antibodies.
Following the results of this study, CytoDyn is planning an initial clinical trial next year to evaluate leronolimab as a human prophylaxis drug. Human doses are less likely than those reported in this study because rhesus monkey cells have more CCR5 protein than humans.
There are other preventative drugs, but their use has some side effects such as liver, heart and bone problems. On the other hand, existing drugs usually have to be used frequently in clinics, but in this research method, the person can also inject.